Cargando…

The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes

SOX2 is a core pluripotency-associated transcription factor causally related to cancer initiation, aggressiveness, and drug resistance by driving the self-renewal and seeding capacity of cancer stem cells (CSC). Here, we tested the ability of the clinically proven inhibitor of the lysine-specific de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cuyàs, Elisabet, Gumuzio, Juan, Verdura, Sara, Brunet, Joan, Bosch-Barrera, Joaquim, Martin-Castillo, Begoña, Alarcón, Tomás, Encinar, José Antonio, Martin, Ángel G., Menendez, Javier A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138538/ https://www.ncbi.nlm.nih.gov/pubmed/32191225 http://dx.doi.org/10.18632/aging.102887

Ejemplares similares

First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia
por: Salamero, Olga, et al.
Publicado: (2020)

Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A
por: Cuyàs, Elisabet, et al.
Publicado: (2019)

Circulating levels of MOTS-c in patients with breast cancer treated with metformin
por: Cuyàs, Elisabet, et al.
Publicado: (2022)

Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity
por: Verdura, Sara, et al.
Publicado: (2020)

Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy
por: Cuyàs, Elisabet, et al.
Publicado: (2020)

Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer
por: Menendez, Javier A., et al.
Publicado: (2020)

Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy
por: Verdura, Sara, et al.
Publicado: (2019)

Metformin: Targeting the Metabolo-Epigenetic Link in Cancer Biology
por: Cuyàs, Elisabet, et al.
Publicado: (2021)

Metformin and breast cancer: an opportunity for pharmacogenetics
por: Cuyàs, Elisabet, et al.
Publicado: (2022)

Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells
por: Verdura, Sara, et al.
Publicado: (2022)

Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors
por: Verdura, Sara, et al.
Publicado: (2022)

In silico clinical trials for anti-aging therapies
por: Menendez, Javier A., et al.
Publicado: (2019)

BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells
por: Cuyàs, Elisabet, et al.
Publicado: (2017)

Metabolomic mapping of cancer stem cells for reducing and exploiting tumor heterogeneity
por: Cuyàs, Elisabet, et al.
Publicado: (2017)

Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells
por: Corominas-Faja, Bruna, et al.
Publicado: (2014)

Mimetics of extra virgin olive oil phenols with anti-cancer stem cell activity
por: Cuyàs, Elisabet, et al.
Publicado: (2020)

Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin
por: Bosch-Barrera, Joaquim, et al.
Publicado: (2021)

Metabolomic and Mitochondrial Fingerprinting of the Epithelial-to-Mesenchymal Transition (EMT) in Non-Tumorigenic and Tumorigenic Human Breast Cells
por: Cuyàs, Elisabet, et al.
Publicado: (2022)

Metformin Is a Direct SIRT1-Activating Compound: Computational Modeling and Experimental Validation
por: Cuyàs, Elisabet, et al.
Publicado: (2018)

Metformin Is a Pyridoxal-5′-phosphate (PLP)-Competitive Inhibitor of SHMT2
por: Tramonti, Angela, et al.
Publicado: (2021)

A Sox2–Sox9 signalling axis maintains human breast luminal progenitor and breast cancer stem cells
por: Domenici, Giacomo, et al.
Publicado: (2019)

Nutritional Niches of Cancer Therapy-Induced Senescent Cells
por: Llop-Hernández, Àngela, et al.
Publicado: (2022)

Heregulin Drives Endocrine Resistance by Altering IL-8 Expression in ER-Positive Breast Cancer
por: Papadimitropoulou, Adriana, et al.
Publicado: (2020)

Accelerated geroncogenesis in hereditary breast-ovarian cancer syndrome
por: Menendez, Javier A., et al.
Publicado: (2016)

Lung Cancer Management with Silibinin: A Historical and Translational Perspective
por: Verdura, Sara, et al.
Publicado: (2021)

Progesterone receptor isoform-dependent cross-talk between prolactin and fatty acid synthase in breast cancer
por: Menendez, Javier A., et al.
Publicado: (2020)

Binding of the angiogenic/senescence inducer CCN1/CYR61 to integrin α(6)β(1) drives endocrine resistance in breast cancer cells
por: Espinoza, Ingrid, et al.
Publicado: (2022)

ORY-1001 Suppresses Cell Growth and Induces Apoptosis in Lung Cancer Through Triggering HK2 Mediated Warburg Effect
por: Lu, Zhaoliang, et al.
Publicado: (2018)

Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas
por: Martin-Castillo, Begoña, et al.
Publicado: (2015)

Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer
por: Menendez, Javier A., et al.
Publicado: (2021)

Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients
por: Bosch-Barrera, Joaquim, et al.
Publicado: (2020)

Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer
por: Queralt, Bernardo, et al.
Publicado: (2016)

Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched for stem cell-like properties
por: Cuyàs, Elisabet, et al.
Publicado: (2015)

Targeting LSD2 in breast cancer
por: Huang, Yi, et al.
Publicado: (2018)

Germline BRCA1 mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: evidence for metformin-based “starvation” strategies in BRCA1 carriers
por: Cuyàs, Elisabet, et al.
Publicado: (2016)

The anti-malarial chloroquine overcomes Primary resistance and restores sensitivity to Trastuzumab in HER2-positive breast cancer
por: Cufí, Sílvia, et al.
Publicado: (2013)

The Activation of the Sox2 RR2 Pluripotency Transcriptional Reporter in Human Breast Cancer Cell Lines is Dynamic and Labels Cells with Higher Tumorigenic Potential
por: Iglesias, Juan Manuel, et al.
Publicado: (2014)

Bacteriemia por Actynomices oris
por: Guerra, Javier Miguel Martín, et al.
Publicado: (2019)

LSD1 suppresses invasion, migration and metastasis of luminal breast cancer cells via activation of GATA3 and repression of TRIM37 expression
por: Hu, Xin, et al.
Publicado: (2019)

Activation of the methylation cycle in cells reprogrammed into a stem cell-like state
por: Fernández-Arroyo, Salvador, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6bmgn7d1q7mor0oltagu87476f